News Releases

News Releases

Synteract Adds General Medicine Center of Development to Meet Market Demand and Further Align with Its Longstanding Experience

RESEARCH TRIANGLE PARK, NC– September 12, 2019Synteract, an innovative contract research organization partnering with biotech and pharma companies to bring new medicines to market, has added a General Medicine Center of Development, focused on women’s health and gastroenterology, to its core development areas in oncology, dermatology, neuroscience, pediatrics, and rare and orphan diseases.. The introduction of this General Medicine Center Of Development leverages Synteract’s demonstrated experience, having historically conducted hundreds of clinical trials in these therapeutic areas.

Formal establishment of its sixth center of development brings a renewed focus with more visibility into Synteract’s deep scientific and operational expertise in high demand areas such as gastroenterology and women’s health, among others that fall in the general medicine sphere. Synteract is honoring the customer relationships established in this space over its history, across multiple projects, having supported them in bringing important medicines to market.

Leading the new General Medicine Center of Development is Linda Rawlings, transitioning from her role as Vice President, Neuroscience to Vice President, General Medicine. Linda has 27 years in the CRO, pharmaceutical and medical device sectors, with a keen focus on developing and implementing strategies designed to deliver excellence at the local, international, and global level.

About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 240 product approvals. Synteract offers a notable depth of expertise in oncology, dermatology, neuroscience, pediatrics, general medicine, and rare and orphan diseases. Connect on LinkedIn and Twitter

# # #

x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required